Consensus Celldex Therapeutics, Inc.

Stocks

CLDX

US15117B2025

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 09:59:15 2026-06-24 EDT			5-day change	1st Jan Change
33.28 ^USD	+0.91%		+1.12%	+22.61%

06-14	Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU	CI
06-14	Celldex Therapeutics, Inc. Presents Positive First-In-Human Results From Phase 1 Study Of Novel Bispecific CDX-622 At The European Academy Of Allergy And Clinical Immunology Annual Meeting	CI

Evolution of the Average Target: Celldex Therapeutics, Inc.

Evolution of the Target Price: Celldex Therapeutics, Inc.

Changes in Analyst Recommendations: Celldex Therapeutics, Inc.

b1dc9c9c1f4670ffab1e3f1f37394146.P9nkDeD6vVWgL4UqiKY14QFwqlPmvNhZt_q6YgK7Aj0.W5XcfpOZ6BLSfvNO5u9PuFk6kiCu-a0U8InyUHvQdAloidFH2KnaH5RlsQ~93700bfa06dcfc80d847415d09b47474

Analysts' recommendations: Celldex Therapeutics, Inc.

06-10	UBS Adjusts Price Target on Celldex Therapeutics to $45 From $38, Maintains Buy Rating	MT
04-20	Barclays Upgrades Celldex Therapeutics to Overweight From Underweight, Adjusts Price Target to $45 From $24	MT
03-23	Celldex Therapeutics Shares Rise After Wolfe Research Upgrade	MT
03-23	Wolfe Research Upgrades Celldex Therapeutics to Outperform From Peer Perform, PT is $44	MT
02-26	Morgan Stanley Lifts Price Target on Celldex Therapeutics to $44 From $43, Keeps Overweight Rating	MT
11-06	Celldex Presents Additional Positive Data Demonstrating Barzolvolimab's Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria Study	CI
25-10-21	Mizuho Initiates Celldex Therapeutics at Outperform With $48 Price Target	MT
25-10-13	Barclays Initiates Celldex Therapeutics at Underweight With $25 Price Target	MT
25-05-09	UBS Adjusts Price Target on Celldex Therapeutics to $38 From $44, Maintains Buy Rating	MT
25-04-28	Canaccord Genuity Initiates Coverage on Celldex Therapeutics With Buy Rating, $64 Price Target	MT
25-03-20	Morgan Stanley Initiates Celldex Therapeutics at Overweight With $46 Price Target	MT
24-10-07	Citigroup Initiates Celldex Therapeutics at Buy With $70 Price Target	MT
24-09-30	Goldman Sachs Initiates Coverage on Celldex Therapeutics With Neutral Rating, $45 Price Target	MT
24-09-27	Wolfe Research Downgrades Celldex Therapeutics to Peer Perform From Outperform	MT
24-09-26	Wells Fargo Upgrades Celldex Therapeutics to Overweight From Equalweight After Barzolvolimab Data	MT
24-09-25	Wells Fargo Upgrades Celldex Therapeutics to Overweight From Equalweight	MT
24-06-18	Stifel Initiates Celldex Therapeutics at Buy Rating With $58 Price Target	MT
24-06-11	Wolfe Research Initiates Coverage on Celldex Therapeutics With Outperform Rating, $51 Price Target	MT
23-12-20	TD Cowen Initiates Celldex Therapeutics at Outperform Rating	MT
23-11-10	Wells Fargo Upgrades Celldex Therapeutics to Equalweight From Underweight With $27 Price Target	MT
23-11-06	HC Wainwright Adjusts Price Target on Celldex Therapeutics to $80 From $73, Maintains Buy Rating	MT
23-08-22	Wells Fargo Starts Celldex Therapeutics With Underweight Rating, $21 Price Target	MT
23-08-22	Analyst recommendations: Applovin, BAE Systems, Evercore, Jefferies, Target...
22-11-11	Guggenheim Adjusts Price Target on Celldex Therapeutics to $63 From $68, Maintains Buy Rating	MT
22-08-09	SVB Securities Adjusts Celldex Therapeutics' Price Target to $64 From $68, Keeps Outperform Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CELLDEX THERAPEUTICS, INC.					+74.45%
	LONZA GROUP AG					+28.75%
	REVOLUTION MEDICINES, INC.					+10.49%
	BEONE MEDICINES AG					+49.33%
	IQVIA HOLDINGS INC.					+31.64%
	CELLTRION, INC.					+58.27%
	ASCENDIS PHARMA A/S					+24.19%
	MEDPACE HOLDINGS, INC.					-6.33%
	EUROFINS SCIENTIFIC SE					+8.87%
	IONIS PHARMACEUTICALS, INC.					+38.06%
	Average					+31.77%
	Weighted average by Cap.					+29.53%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

32.98USD

Average target price

57.53USD

Spread / Average Target

+74.45%

High Price Target

90.00USD

Spread / Highest target

+172.89%

Low Price Target

38.00USD

Spread / Lowest Target

+15.22%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

UBS
Barclays
Wolfe Research
Morgan Stanley
Mizuho Securities
Canaccord Genuity
Citigroup
Goldman Sachs
Wells Fargo Securities
Stifel Nicolaus
TD Cowen
HC Wainwright
Guggenheim
SVB Securities LLC
Jefferies & Co.
SVB Leerink